This is supported by the increased overall (HFD: p53+/− vs. Sirt3−/−; p53+/−p < 0.0001) and median (HFD: 293 days p53+/− vs. 406 days Sirt3−/−; p53+/−) survival, as well as decreased tumor incidence (HFD: p53+/− vs. Sirt3−/−; p53+/−p = 0.002) (Figures 5C,D and Supplementary Table 1). This evidence concerns the gene TP53 and neoplasm.